Induction of durable remission in ocular inflammatory diseases

European Journal of Ophthalmology

Volumn 19, Issue 1, 2009, Pages 118-123

  Cervantes Castaneda R A ^a   Bhat, P ^a   Fortuna, E ^a   Acevedo, S ^a   Foster, C Stephen ^a,b  

^a MASSACHUSETTS EYE RESEARCH AND SURGERY INSTITUTION   (United States)

^b Massachusetts Eye Research and Surgery Institute   (United States)

Author keywords

Durable remission; Induction of remission in uveitis; Remission in uveitis

Indexed keywords

AZATHIOPRINE; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DACLIZUMAB; DAPSONE; ETANERCEPT; IMMUNOGLOBULIN G; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CORNEA NEOVASCULARIZATION; CORTICOSTEROID THERAPY; DRUG INDUCED HEADACHE; DRUG TREATMENT FAILURE; EYE EDEMA; EYE INFLAMMATION; FATIGUE; FEMALE; HERPES ZOSTER; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INTERMEDIATE UVEITIS; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MUCOUS MEMBRANE PEMPHIGOID; NAUSEA; OPTIC NERVE DISEASE; PRIORITY JOURNAL; RASH; REMISSION; RETROSPECTIVE STUDY; SIDE EFFECT; UVEITIS; VIRAL RESPIRATORY TRACT INFECTION; VISUAL ACUITY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT FAILURE; UVEITIS; YOUNG ADULT;

EID: 69249158783     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.1177/112067210901900117     Document Type: Article

References (29)

1. Suttorp-Schulten MS, Rothova A. The possible impact of uveitis in blindness: a literature survey. Br J Ophthalmol 1996; 80: 844-8.
2. Nussenblatt RB. Immunoregulation of uveitis. Int Ophthalmol 1990; 14: 13-8.
3. Rothova A, Suttorp-Schulten MS, Treffers WF, et al. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol 1996; 80: 332-6.
4. Rosenberg AM. Uveitis associated with juvenile idiopathic arthritis: envisioning the future. J Rheumatol 2002; 29: 2253-5.
5. Ozdal PC, Vianna RN, Deschênes J. Visual outcome of juvenile rheumatoid arthritis-associated uveitis in adults. Ocul Immunol Inflamm 2005; 13: 33-8.
6. Thorne JE, Jabs DA, Peters GB, Hair D, Dunn JP, Kempen JH. Birdshot retinochoroidopathy: ocular complications and visual impairment. Am J Ophthalmol 2005; 140: 45-51.
7. Roda E. Uveitis treated with nitrogen mustard. Am J Ophthalmol 1952; 35: 114.
8. Newell FW, Krill AE. Treatment of uveitis with azathioprine. Br J Ophthalmol 1968; 52: 688-90.
9. Buckley CE, Gills JP. Cyclophosphamide therapy of peripheral uveitis. Arch Intern Med 1969; 124: 29-35.
10. Mamo JG, Azzam SA. Treatment of Behçet's disease with chlorambucil. Arch Ophthalmol 1970; 84: 446-50.
11. Andrasch RH, Pirofsky B, Burns RP. Immunosuppressive therapy for severe chronic uveitis. Arch Ophthalmol 1978; 96: 247-51.
12. Wallece C, Ruperto N, Giannini E, et al. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 2004; 31: 2290-4.
13. Wallace C, Ravelli A, Huang B, et al. Preliminary validation of clinical remission criteria using the OMERACT filter for select categories of juvenile idiopathic arthritis. J Rheumatol 2006; 33: 789-95.
14. Chang JH, McCluskey PJ, Wakefield D. Acute anterior uveitis and HLA-B27. Surv Ophthalmol 2005; 50: 364-88.
15. Yu EN, Meniconi ME, Tufail F, et al. Outcomes of treatment with immunomodulatory therapy in patients with corticosteroid-resistant juvenile idiopathic arthritis-associated chronic iridocyclitis. Ocul Immunol Inflamm 2005; 13: 353-60.
16. Shah K, Levinson R, Yu F, et al. Birdshot chorioretinopathy. Surv Ophthalmol 2005; 50: 519-41.
17. de Boer J, Berendschot TT, van der Does P, Rothova A. Long-term follow-up of intermediate uveitis in children. Am J Ophthalmol 2006; 141: 616-21.
18. Mamo JG. The rate of visual loss in Behçet's disease. Arch Ophthalmol 1970; 84: 451-2.
19. Uyama M. Uveitis in sarcoidosis. Int Ophthalmol Clin 2002; 42: 143-50.
20. Laatikainen L, Erkkila H. A follow-up study on serpiginous choroiditis. Acta Ophthalmol 1981; 59: 707-8.
21. Hooper PL, Secchi AG, Kaplan HJ. Serpiginous choroiditis. In: Pepose JS, Holland GN, Wilhelmus KR. Ocular Infection and Immunity. St. Louis: Mosby, 1996; 579-84.
22. Weiss H, Annesley WH, Shields JA, et al. The clinical course of serpiginous choroidopathy. Am J Ophthalmol 1979; 87: 133-42.
23. Andreoli CM, Foster CS. Vogt-Koyanagi-Harada disease. Int Ophthalmol Clin 2006; 46: 111-22.
24. Damico FM, Kiss S, Young LH. Vogt-Koyanagi-Harada disease. Semin Ophthalmol 2005; 20: 183-90.
25. Kim EC, Foster CS. Immunomodulatory therapy for the treatment of ocular inflammatory disease: evidence-based medicine recommendations for use. Int Ophthalmol Clin 2006; 46: 141-64.
26. Biester S, Deuter C, Michels H, et al. Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol 2007; 91: 319-24.
27. Choudhary A, Harding SP, Bucknall RC, Pearce IA. Mycophenolate mofetil as an immunosuppressive agent in refractory inflammatory eye disease. J Ocul Pharmacol Ther 2006; 22: 168-75.
28. Galor A, Perez VL, Hammel JP, Lowder CY. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology 2006; 113: 2317-23.
29. Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 2000; 130: 492-513.